Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.

Article Details

Citation
Copy to clipboard

Nee J, Zakari M, Lembo AJ

Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.

Expert Opin Pharmacother. 2015 Dec;16(18):2781-92. doi: 10.1517/14656566.2015.1101449. Epub 2015 Nov 11.

PubMed ID
26558923 [ View in PubMed
]
Abstract

INTRODUCTION: Irritable bowel syndrome diarrhea predominant (IBS-D) is a highly prevalent GI disease, affecting nearly a third of all patients diagnosed with irritable bowel syndrome. Current treatment options are limited. AREAS COVERED: This review discusses the pharmacotherapeutic options for IBS-D including currently used medications, the two newly FDA approved medications, as well as emerging therapies with potential benefit in IBS-D. Particular emphasis is placed on rifaximin and eluxadoline and their possible use in IBS-D. EXPERT OPINION: Current pharmacological treatment of IBS-D includes loperamide, bile acid sequestrants, antispasmodics, tricyclic antidepressants, alosetron, eluxadoline and rifaximin. The latter two treatments have significantly added to the pharmacotherapeutic options for patients suffering from IBS-D.

DrugBank Data that Cites this Article

Drugs